The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase II study of CPX-351 in younger patients < 60 years old with secondary acute myeloid leukemia: Trial in progress.
 
Mahesh Swaminathan
No Relationships to Disclose
 
Salman Fazal
No Relationships to Disclose
 
Elizabeth A. Griffiths
Honoraria - Novartis
Consulting or Advisory Role - Abbvie; Alexion Pharmaceuticals; Celgene/Bristol-Myers Squibb; CTI BioPharma Corp; Genentech; Novartis; Otsuka; PicnicHealth; Taiho Oncology; Takeda
Research Funding - Apellis Pharmaceuticals (Inst); Astex Pharmaceuticals (Inst); Astex Pharmaceuticals (Inst); Bristol-Myers Squibb/Celgene; Celgene (Inst); Celldex (Inst); Genentech (Inst)
 
James E. Thompson
Research Funding - Bristol-Myers Squibb (Inst); Novartis (Inst)
 
Pamela Jeannette Sung
No Relationships to Disclose
 
Steven Daniel Green
No Relationships to Disclose
 
Emily Li
No Relationships to Disclose
 
Meriem Said
No Relationships to Disclose
 
Krista Belko
No Relationships to Disclose
 
Emmalyn Mattice
No Relationships to Disclose
 
Kristopher Attwood
No Relationships to Disclose
 
Eunice S. Wang
Consulting or Advisory Role - Abbvie; Astellas Pharma; Celgene/Bristol-Myers Squibb; Genentech; Gilead Sciences; GlaxoSmithKline; Jazz Pharmaceuticals; Kite/Gilead; Novartis; Pfizer; Pharmaessentia; PTC Therapeutics; Stemline Therapeutics; Takeda
Speakers' Bureau - Astellas Pharma; dava oncology; Kite, a Gilead company; Pfizer; Stemline Therapeutics
 
Amanda Przespolewski
No Relationships to Disclose